AbbVie Down Since Q4 Earnings Report: How to Play the Stock

Key Takeaways AbbVie beat Q4 estimates and sees 9.5% revenue growth in 2026 despite Humira erosion.Skyrizi and Rinvoq delivered $26B in 2025 sales, up 40% , with over $31B projected for 2026.Aesthetics and oncology face pressure, but AbbVie's pipeline and M&A aim to drive long-term growth.AbbVie (ABBV) stock felt some downward pressure despite reporting better-than-expected fourth-quarter results on Feb. 4. AbbVie beat estimates for both earnings and sales and also issued an upbeat outlook for 2026, yet the ...